RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer
15 Jan, 2023 | 20:05h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023